This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Time independent factors that predict relapse in adults with acute myeloid leukemia
Blood Cancer Journal Open Access 15 January 2024
-
Have we been qualifying measurable residual disease correctly?
Leukemia Open Access 13 September 2023
-
Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models
Leukemia Open Access 07 August 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2015; 29: 312–320.
Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia 2015; 29: 2104–2107.
Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854–4860.
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 2016; 34: 329–336.
Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB et al. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 2016; 30: 1456–1464.
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417–4423.
Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42 A study. J Clin Oncol 2013; 31: 3889–3897.
Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123–4131.
Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 2015; 33: 1258–1264.
Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007; 110: 4172–4174.
Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009; 23: 350–357.
Vainstein V, Buckley SA, Shukron O, Estey EH, Abkowitz JL, Wood BL et al. Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 2014; 28: 713–716.
Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R et al. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the ‘3+7’ induction regimen for acute myeloid leukemia. Am J Hematol 2015; 90: 1159–1164.
Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944–4951.
Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016; 374: 422–433.
Acknowledgements
Research reported in this publication was supported by grants from the National Cancer Institute/National Institutes of Health (NCI/NIH; CA182010 to RBW and MO, CA160872 to DLS, and CA090998 to MO). The S0106 study was conducted by SWOG and supported by NIH/NCI/NCTN Grants CA180888, CA180819, CA180828 and CA180944; NCI Grant CA182010, and in part by Wyeth (Pfizer) Pharmaceuticals, Inc. RBW is a Leukemia & Lymphoma Society Scholar in Clinical Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Othus, M., Wood, B., Stirewalt, D. et al. Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia 30, 2080–2083 (2016). https://doi.org/10.1038/leu.2016.120
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.120
This article is cited by
-
Perspective on measurable residual disease testing in acute myeloid leukemia
Leukemia (2024)
-
Time independent factors that predict relapse in adults with acute myeloid leukemia
Blood Cancer Journal (2024)
-
Have we been qualifying measurable residual disease correctly?
Leukemia (2023)
-
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis
Leukemia (2022)
-
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation (2022)